NCT03899324View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease

PHASE2UnknownINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

August 31, 2021

Conditions

Parkinson Disease

Interventions

DRUG

Bumetanide white, oblong, scored tablet

Bumetanide with a titration period

DRUG

Placebo white, oblong, scored tablet

placebo intake identically to group 1

Trial Locations (1)

44093

RECRUITING

Chu Nantes, Nantes

Sponsors

Lead Sponsor

B&A Therapeutics

All Listed Sponsors

lead

B&A Therapeutics

INDUSTRY

NCT03899324 - Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease | Biotech Hunter | Biotech Hunter